Simple. Powerful. Fast.
Immune System Monitoring with CyTOF
You need answers from every cell in each precious patient sample, and you need them quickly, reliably.
Mass cytometry, powered by CyTOF® technology, can expedite COVID-19 therapeutic and vaccine research studies with best-in-class, highly multiplexed, longitudinal immune monitoring capability.
Faster and more cost-efficient than single-cell RNA-seq, CITE-seq or AbSeq, mass cytometry also provides deeper resolution of immune cell phenotype and function than any flow cytometry or spectral cytometry system.
In this presentation, Marcelo B. Sztein, MD, shows examples of his group’s use of mass cytometry to help advance the fields of vaccine development and pathogen-host interactions. He provides an in-depth look at his studies of Salmonella typhi (S. typhi), the causative agent of typhoid fever, an infectious disease of great public health importance. Register to watch
“We chose the Maxpar Direct Immune Profiling Assay for this study* because it provides a robust and standardized solution for comprehensive immune monitoring that is technically easy to execute and harmonize across multiple study sites.”
—Adeeb Rahman, PhD
Icahn School of Medicine at Mount Sinai
* Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC)
De Smet presents early data from the COvid-19 Advanced Genetic and Immunologic Sampling (COntAGIouS) clinical research study (NCT04327570) using the Maxpar® Direct™ Immune Profiling Assay™ and Maxpar Pathsetter™ software. Watch now
Professor Frederik De Smet, MSc, PhD
Assistant Professor
University of Leuven, Belgium
Ruth Montgomery, PhD, describes her team’s work using mass cytometry in infectious disease studies and how her team will contribute to the IMPACC study by analyzing endotracheal aspirates from participants. Watch now
Ruth Montgomery, PhD
Professor of Internal Medicine
Director, Yale CyTOF Facility
Associate Dean for Scientific Affairs
Resources
Published research and trials using the Maxpar Direct Immune Profiling Assay
Download a summary of COVID-19 trials and publications using CyTOF. Download now
Publications
Hadjadj, J. et al. “Impaired type I interferon activity and exacerbated inflammatory responses in severe COVID-19 patients.” Science (2020): 718–724.
Ausar, S.F. et al. “Genetically detoxified pertussis toxin displays near identical structure to its wild-type and exhibits robust immunogenicity.” Communications Biology 3 (2020): 427.
Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) (NCT04378777)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); 10 participating institutions in North America
Chng, M.H.Y. et al. “Large-scale HLA tetramer tracking of T cells during dengue infection reveals broad acute activation and differentiation into two memory cell fates.” Immunity 51 (2019): 1,119–1,135.
Lucchesi, S. et al. “From bivariate to multivariate analysis of cytometric data: overview of computational methods and their application in vaccination studies.” Vaccines 8 (2020): 138.
Newell E.W. et al. “Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization.” Nature Biotechnology 31 (2013):623–629.
Palgen, J-L. et al. “Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations.” npj Vaccines (2020): 24.
Rudolph, M.E. et al. “Diversity of Salmonella Typhi-responsive CD4 and CD8 T cells before and after Ty21a typhoid vaccination in children and adults.” International Immunology (2019): 315–333.
Tomic, A. et al. “The FluPRINT dataset, a multidimensional analysis of the influenza vaccine imprint on the immune system.” Scientific Data 6 (2019): 214.
Get more information.
For Research Use Only. Not for use in diagnostic procedures.
